A study Scholtzova et al. (2017) used a TLR-9 agonist: class B cytosine–phosphate–guanine (CpG) oligodeoxynucleotides (ODNs) in a triple transgenic mice model (Tg-SwD), which had significant cerebral amyloid angiopathy (CAA) and observed that CpG ODN reduced CAA and improved cognition, implicating TLR-9 in microglial activation [126]. The gene discussed is TLR9; the disease is cerebral amyloid angiopathy.